NASDAQ | DRNA

$14.13 - 0.32 (-2.215%)

3 month stock price graph

4:00 PM ET on Jul 2, 2015 Pricing delayed 20 minutes

Investors & Media

Press Releases

 
Press Releases
  Date Title and Summary View
Jul 1, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today announced that on June 30, 2015, the Compensation ...
Jun 19, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the JMP Securities Life Sciences Conference. The presentation ...
Jun 11, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) today responded to a complaint filed yesterday by Alnylam Pharmaceuticals, Inc. in the Superior Court of Middlesex County, Massachusetts. Dicerna believes the complaint is meritless and that Alnylam precipitously filed its lawsuit ...
Jun 1, 2015
Evidence of Clinical Anti-tumor Activity Seen in Two Patients with Advanced Pancreatic Neuroendocrine Tumors CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi therapeutics, today presented preliminary safety and efficacy ...
May 29, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Jefferies 2015 Healthcare Conference. The presentation wil...
May 20, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) ("Dicerna"), announced today the pricing of its underwritten registered public offering of 2,750,000 shares of its common stock at a price to the public of $17.75 per share. Closing of the offering is expected to occur on May 27, 2015...
May 18, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) ("Dicerna"), announced today the commencement of a proposed underwritten public offering of 2,750,000 shares of common stock. Dicerna also intends to grant the underwriters a 30-day option to purchase up to an additional 412,500 share...
May 14, 2015
New Cohort Added Based on Signs of Clinical Activity in PNET Patients CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi therapeutics, today announced it is expanding its ongoing Phase 1 study of DCR-MYC in solid tumors, multi...
May 13, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi therapeutics, today announced that new clinical data from a Phase 1 study of DCR-MYC in patients with solid tumors, multiple myeloma, or lymphoma will be presented at the 2015 American Society of ...
May 11, 2015
-Management to Host Conference Call Today at 4:30 pm ET- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced financial and operational results for the quarter ended March 31, 2015. ...
May 6, 2015
TIDES Presentation Describes New, Proprietary Approach for Delivery to the Liver via Subcutaneous Injection CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNA interference (RNAi) therapeutics, today presented preclinic...
May 4, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference therapeutics, today announced that Bob D. Brown, Ph.D., chief scientific officer, will present preclinical conjugate data at the 17th Annual TIDES: Oligonucleotide and Peptide...
Apr 29, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Deutsche Bank 40th Annual Health Care Conference. Th...
Apr 29, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics, announced that the Company will release its first quarter 2015 financial results after market close on Monday, May 11, 2015. Management wil...
Apr 23, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCR-PH1, the company's therapeutic candidate for the treatment of ...
Apr 10, 2015
Data Show Robust Silencing of CTNNB1 Gene in Patient-Derived Xenograft and Other Cancer Models Using RNAi CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi therapeutics, today announced promising new in vivo data for...
Mar 31, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today announced that on March 31, 2015, the Compensation...
Mar 12, 2015
-Management to Host Conference Call Today at 4:30 pm ET- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting rare inherited diseases involving the liver and genetically defined cancers, to...
Mar 9, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that the Company will release its fourth quarter and full year 2014 financial results after market close on Thursday, March 12, 2015. M...
Feb 26, 2015
Relocation Reflects Company's Continued Growth and Accommodates Future Expansion CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi therapeutics, today celebrates the opening of a new 37,000 square-foot office and st...
Feb 4, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will presen...
Feb 2, 2015
Trial to Evaluate Safety, Tolerability and Preliminary Antineoplastic Effect of DCR-MYC CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi therapeutics, today announced that the first patient has been dosed in a globa...
Jan 12, 2015
Claims of US Patent No. 8,927,705 Cover Composition of Matter of Dicerna's Next-Generation Proprietary Payloads for RNAi Therapeutics and Self-Targeting Conjugates WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi th...
Jan 12, 2015
Data Provide New Insights into DsiRNA Delivery and Activity in Hepatocellular Carcinoma and Colorectal Cancer WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi therapeutics, today announced the presentation of new pr...
Dec 17, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. ("Dicerna" or the "Company") (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced the appointment of Theodore (Ted) T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations. Dr. As...
Dec 15, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, announces webcast and conference call information for its previously announced R&D Update webcast lat...
Nov 25, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced that Douglas M. Fambrough, Ph.D., President and CEO, will present at the 2014 Deutsch...
Nov 17, 2014
-- Company to Host First R&D Webcast on December 15 -- WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNA interference (RNAi) based therapeutics, today announced that it will host its first R&D webcast to review the company's s...
Nov 17, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced a licensing agreement for Dicerna to use Tekmira's proprietary lipid nanoparticle (LNP) technology for delivery of DCR-PH1, Dicerna's investigational produc...
Nov 14, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced that Douglas M. Fambrough, Ph.D., President and CEO, will present at two upcoming co...
Nov 6, 2014
-Management to Host Conference Call Today at 8:30 am ET- WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced finan...
Oct 24, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that the Company will release its third-quarter 2014 financial results before market open on Thursday, November 6, 2014. Management wil...
Oct 14, 2014
Poster Highlights Rapid and Durable Effect of DCR-PH1 in Mouse Model of PH1 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, presented data from its preclinical program in primary hyperoxaluria t...
Sep 29, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, President and CEO, will present at three upcoming conferences, including the 2014 Leerink Rare Disease Roundtable, Berns...
Sep 15, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, announced today the appointment of Bruce Peacock to its board of directors and audit committee. Mr. Peacock currently serves as chief financial and business officer at Ophthotec...
Sep 2, 2014
Attending the FBR Inaugural Healthcare Conference WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, President and CEO, will present at the 2014 ...
Aug 21, 2014
US PTO 8,809,515 "515" Provides Opportunity to Design, Optimize and Target Dicerna's DsiRNAs in Drug Development WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced a series of recently issue...
Aug 7, 2014
-Management to Host Conference Call Today at 4:30 pm ET- WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced opera...
Jul 25, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that the Company will release its second-quarter 2014 financial results after market close on Thursday, August 7. Management w...
Jul 11, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that the Company will ring the NASDAQ Stock Market closing bell on Tuesday, July 15, 2014. "Dicerna has achieved significant milestones in the f...
Jun 30, 2014
DCR-PH1 Uses Proprietary Dicer Substrate RNAi Technology to Inhibit Enzyme Implicated in Rare Liver Disorder WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced the presentati...
Jun 19, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company's President and CEO, will present at the 9th Annual JMP Securities Healthcare Conference on June 24 2014, at 1:00 PM...
May 23, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, President and CEO, will present at Jefferies 2014 Global Healthcare Conference on June 2, 2014, at 10:00am ET in New York, NY. I...
May 19, 2014
Watertown, MA, May 19, 2014 - Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the Company received the "Deal of the Year- Healthcare" award at the 2014 NEVY Awards, a celebration of the most innovative and exciting companies in Boston hosted by the New England Venture...
May 13, 2014
- DCR-MYC Becomes First Dicer Substrate RNA Interference Drug Candidate to Enter Clinical Trials - - Management to Host Conference Call at 4:30 PM ET - WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RN...
May 8, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, will report its first quarter 2014 financial results on May 13, 2014. Dicerna will host a conference call and live audio webcast on May 13, 2014, at 4:30 p.m. (ET) to ...
Apr 18, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that it granted stock options to Pankaj Bhargava, M.D., the Company's chief medical officer, on April 16, 2014, including a stock option to purchase 246,406 ...
Apr 16, 2014
-DCR-MYC is the First Dicer Substrate RNA Interference Candidate to Advance into Clinical Testing- WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the initiation of a Phase 1 do...
Apr 2, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the appointment of Pankaj Bhargava, M.D., as Chief Medical Officer. Dr. Bhargava brings to Dicerna more than 15 years of experience in oncology drug development...
Mar 27, 2014
-DCR-M1711 to Enter Phase 1 Clinical Trials in First Half of 2014- -Management to Host Conference Call at 4:30 PM ET- WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today provided a cor...
Mar 25, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company's President and CEO, is scheduled to present at the 21st Annual Future Leaders in the Biotech Industry conf...
Mar 24, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, will report its fourth quarter 2013 financial results on March 27, 2014. Dicerna will host a conference call and live audio webcast on March 27, 2014 at 4:30 p.m. (ET) to ...
Mar 6, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced that members of the management team will present at two upcoming conferences: Bernstein Emerging Biotech Conference 2014, Snowbird, U...
Feb 24, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced that Bob D Brown, PhD, the Company's Chief Scientific Officer and SVP, is scheduled to participate in the 2014 AsiaTIDES Conference being held in Tokyo, Japan Fe...
Feb 7, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company's President and CEO, is scheduled to present at the 2014 Leerink Global Healthcare Conference on Thursday, February ...
Feb 5, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced its participation in a panel discussion on RNAi therapeutics at the 16th Annual BIO CEO & Investor Conference. Douglas M. Fambrough, PhD, the company's President...
Feb 4, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) today announced the closing of its initial public offering of 6,900,000 shares of common stock, including 900,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shar...
Jan 29, 2014
Watertown, MA, January 29, 2014 - Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. In addition, Dicerna has granted the underwriters a 30-day option to purchase up to an additional...
Jan 4, 2014
Oct 9, 2013
Aug 1, 2013
Jul 1, 2013
Apr 2, 2013
Mar 19, 2013
Jan 3, 2013
Oct 24, 2012
Sep 17, 2012
Aug 8, 2012
Jan 4, 2012
Dec 15, 2011
Nov 1, 2011
Sep 6, 2011
Jun 8, 2011
Feb 28, 2011
Dec 7, 2010
Nov 3, 2010
Nov 2, 2010
Oct 21, 2010
Sep 30, 2010
Sep 15, 2010
Sep 9, 2010
Aug 11, 2010
Jun 23, 2010
Jun 6, 2010
May 6, 2010
Mar 30, 2010
Sep 21, 2009
Sep 2, 2009
Aug 3, 2009
Jul 21, 2009
Jul 8, 2009
Jun 4, 2009
May 13, 2009
Apr 27, 2009
Mar 24, 2009
Mar 18, 2009
Nov 26, 2008
Nov 20, 2008
Nov 17, 2008
Oct 22, 2008
Oct 16, 2008
Oct 15, 2008
Oct 1, 2008
Jul 15, 2008
Jun 9, 2008
Jan 29, 2008
Nov 14, 2007
= add release to Briefcase